Adamas Pharmaceuticals Was Bought Out and Flexion Therapeutics in Talks for a Buyout Offer
Adamas Pharmaceuticals
Adamas Pharmaceuticals is a healthcare company located in Oakland, California. They focus on drug manufacturing, and they discover and develop drugs for neurologic diseases in the United States.
On Monday, it was announced that Adamas was bought out by Supernus Pharmaceuticals, another biotech firm, for about $400 million. This gives Supernus access to possible Parkinson’s drugs, along with other neurological disorders. Shareholders of Adamas are receiving $8.10 per share, and they get additional benefits depending on how the drugs perform. Due to the news, Adamas closed the day at $8.07, up 75.05%.
Flexion Therapeutics
Flexion Therapeutics is a healthcare company that is on the other side of the US in Boston, Massachusetts. They focus on creating drugs to solve muscular system disorders, and they have a market cap of $461.179 million.
Flexion announced on Monday that they were nearing a deal for Pacira BioSciences to buy them for $630 million. It is a massive premium to Flexion’s market cap last week, and it diversifies Pacira’s non-opioid drugs. It also allows for Flexion’s drugs to be more available for consumers, which can help treat many. Overall, investors loved the acquisition as Flexion ended the day at $9.17, up 58.65%.
I am not a financial advisor and my comments should never be taken as financial advice. Investments come with risk, so always do your research and analysis beforehand.